FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
0xygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
carbon dioxide-air mixture
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
Advanced Solutions Life Sciences
INHALATION · GAS
2020
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2018
NDA30/100
OXYGEN, USP
oxygen/nitrogen 25/75
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
nitrogen
Peak
Advanced Solutions Life Sciences
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
Universal Cells
INHALATION · GAS
2018
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2017
NDA30/100
OXYGEN, USP
oxygen
Peak
Advanced Solutions Life Sciences
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
Advanced Solutions Life Sciences
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
Advanced Solutions Life Sciences
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYGEN, USP
oxygen
Peak
INHALATION · GAS
2013
NDA30/100
OXYTROL FOR WOMEN
oxybutynin
Peak
AbbVie
TRANSDERMAL · FILM, EXTENDED RELEASE
2013
NDA30/100
PACLITAXEL
paclitaxel
Peak
INTRAVENOUS · POWDER
breast cancer after failure of combination chemotherapy for metastatic diseaserelapse within 6 months of adjuvant chemotherapy+2
2022
NDA30/100
PALONOSETRON HYDROCHLORIDE
palonosetron hydrochloride
Peak
Hikma
INTRAVENOUS · SOLUTION
2016
NDA30/100
PALONOSETRON HYDROCHLORIDE
palonosetron hydrochloride
Peak
Fresenius Kabi
INTRAVENOUS · SOLUTION
2017
NDA30/100
PANTOPRAZOLE SODIUM
pantoprazole sodium
Peak
Hikma
INTRAVENOUS · POWDER
pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults
2017
NDA30/100
PARICALCITOL
paricalcitol
Peak
Pfizer
INTRAVENOUS · SOLUTION
2014
NDA30/100